drugset / Trial / NCT01106170

Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure

NCT01106170 ↗

Phase 1 Completed 20 enrolled University of Utah
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to determine if a supplement called Provex CV can reduce blood pressure and other risk factors for heart disease. Heart disease is the leading cause of death in this country and it is important to identify dietary factors, including supplements, that can reduce heart disease risk factors. The supplement to be tested in this study is made of a combination of natural compounds found in plants such as grapeseed extract, green tea, and quercetin. Each compound individually has been shown to improve blood pressure or reduce inflammation. We hypothesize that Provex CV will reduce blood pressure and levels of inflammatory cytokines hypertensive patients with symptoms of metabolic syndrome. This investigational trial of Provex CV has been approved by the United States Food and Drug Administration.

Timeline

Start
2010-03
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Provex CV Unknown 330 mg Oral

Indications